Astellas Pharma Inc
TSE:4503
Intrinsic Value
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. [ Read More ]
The intrinsic value of one
Astellas Pharma Inc
stock under the Base Case scenario is
1 935.15
JPY.
Compared to the current market price of 1 480.5 JPY,
Astellas Pharma Inc
is
Undervalued by 23%.
Astellas Pharma Inc's market capitalization is 2.7T JPY.
Astellas Pharma Inc stock price is 1 480.5 JPY.
Astellas Pharma Inc stock price (1480.5 JPY) is 23% less than its Intrinsic Value (1 935.15 JPY).
Astellas Pharma Inc stock (980.54 JPY) is 34% less than its price (1480.5 JPY). Open DCF Valuation
Astellas Pharma Inc stock price (1480.5 JPY) is 49% less than its Relative Value (2 889.76 JPY). Open Relative Valuation
Astellas Pharma Inc has upside potential of 49% compared to the average analyst price target.
Open Wall St Estimates
Astellas Pharma Inc has positive Net Debt. This means that the company has more debt (464B JPY) than cash and short-term investments (285B JPY).
Astellas Pharma Inc has positive Net Income for the last twelve months.
Astellas Pharma Inc's Revenue is forecast to grow at a rate of 6% per year over the next 3 years.
Astellas Pharma Inc has positive Operating Income for the last twelve months.
Astellas Pharma Inc has positive three-year average ROE (Return on Equity): 8%. The company is efficient at transforming stockholders' equity into net income.
Astellas Pharma Inc has positive three-year average ROIC (Return on Invested Capital): 8%. The company is efficient at using invested capital to generate operating income.
Astellas Pharma Inc's ROE (Return on Equity) has decreased in the last 3 years from 9% to 2%.
Astellas Pharma Inc's short-term liabilties (1T JPY) exceed its short-term assets (1T JPY).
Astellas Pharma Inc's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 3%.
Astellas Pharma Inc's ROE (Return on Equity) for the past 12 months is very low and is equal to 2%.
Astellas Pharma Inc's ROIC (Return on Invested Capital) has decreased in the last 3 years from 11% to 3%.
Astellas Pharma Inc's Revenue has grown by an exceptional 31% over the past 12 months.
Astellas Pharma Inc's Revenue has been growing by 15% per year for the last 3 years.
Astellas Pharma Inc's long-term assets (3T JPY) exceed its long-term liabilties (2T JPY).
Astellas Pharma Inc has positive Free Cash Flow for the last twelve months.
Astellas Pharma Inc's Altman Z-Score is equal to 1.89.
Astellas Pharma Inc has positive Gross Profit for the last twelve months.
Astellas Pharma Inc's D/E (Debt to Equity) is very low and is equal to 0.31.
Valuation Backtest
Astellas Pharma Inc
Run backtest to discover the historical profit from buying and selling
Astellas Pharma Inc
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Astellas Pharma Inc
Balance Sheet Decomposition
Astellas Pharma Inc
| Current Assets | 1.1T |
| Cash & Short-Term Investments | 285.4B |
| Receivables | 505.9B |
| Other Current Assets | 258.8B |
| Non-Current Assets | 2.3T |
| Long-Term Investments | 117.2B |
| PP&E | 289B |
| Intangibles | 1.8T |
| Other Non-Current Assets | 72B |
| Current Liabilities | 1.2T |
| Accounts Payable | 150.4B |
| Other Current Liabilities | 1T |
| Non-Current Liabilities | 711.7B |
| Long-Term Debt | 463.8B |
| Other Non-Current Liabilities | 247.9B |
Earnings Waterfall
Astellas Pharma Inc
|
Revenue
|
1.9T
JPY
|
|
Cost of Revenue
|
-350.5B
JPY
|
|
Gross Profit
|
1.6T
JPY
|
|
Operating Expenses
|
-1.4T
JPY
|
|
Operating Income
|
142B
JPY
|
|
Other Expenses
|
-104.7B
JPY
|
|
Net Income
|
37.3B
JPY
|
Free Cash Flow Analysis
Astellas Pharma Inc
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Astellas Pharma Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Astellas Pharma Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Astellas Pharma Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Astellas Pharma Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Astellas Pharma Inc
According to Wall Street analysts, the average 1-year price target for
Astellas Pharma Inc
is 2 208.69 JPY
with a low forecast of 1 515 JPY and a high forecast of 3 328.5 JPY.
Shareholder Return
Price
Astellas Pharma Inc
| Average Annual Return | 9.61% |
| Standard Deviation of Annual Returns | 15.2% |
| Max Drawdown | -38% |
| Market Capitalization | 2.7T JPY |
| Shares Outstanding | 1 792 989 952 |
| Percentage of Shares Shorted |
N/A
|
News
Last Important Events
Astellas Pharma Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Astellas Pharma Inc
Company Profile
Astellas Pharma Inc
Country
Industry
Market Cap
Dividend Yield
Description
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 15,455 full-time employees. The firm mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one
Astellas Pharma Inc
stock under the Base Case scenario is
1 935.15
JPY.
Compared to the current market price of 1 480.5 JPY,
Astellas Pharma Inc
is
Undervalued by 23%.
You don't have any saved screeners yet
